XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial

Luca Testa, Gaetano Pero, Mario Bollati, Matteo Casenghi, Antonio Popolo Rubbio, Magdalena Cuman, Raul Moreno, Antoni Serra, Joan Antoni Gomez, Francesco Bedogni, Luca Testa, Gaetano Pero, Mario Bollati, Matteo Casenghi, Antonio Popolo Rubbio, Magdalena Cuman, Raul Moreno, Antoni Serra, Joan Antoni Gomez, Francesco Bedogni

Abstract

Background: Thin strut 3rd generation drug eluting stents offer the potential advantage over the previous generation of better technical performance and reduced neointimal proliferation parameters, which are linked to mid and late term device failure.

Aim: To evaluate the performance of the Xlimus sirolimus-eluting stent (SES) against the Synergy everolimus-eluting stent (EES) in terms of device reendothelialization in patients undergoing PCI for coronary artery disease (CAD).

Methods: XLIMIT is a multicenter randomized controlled trial targeting 180 patients requiring percutaneous coronary interventions (PCI). Patients will be treated with Xlimus SES or Synergy EES implantation and randomization will be performed in a 2:1 ratio. The primary endpoint will be the reendothelialization grade of the Xlimus stent in terms of strut coverage and neointimal hyperplasia volume as compared to Synergy. Secondary endpoints will be represented by clinical and procedural outcomes. The first patient was enrolled on February 2019.

Conclusions: A clearer understanding of the endothelialization process of new generation DES could significantly impact the treatment with dual antiplatelet therapy in the future. Moreover, although not powered for clinical end-points, the XLIMIT trial will provide randomized data in a population with minimal exclusion criteria.

Trial registration: ClinicalTrials.gov Identifier: NCT03745053. Registered on November 19, 2018.

Keywords: Clinical trials; Coronary artery disease; Drug-eluting stent.

Figures

Fig. 1
Fig. 1
TVR: target vessel revascularization; TV MI: target vessel myocardial infarction; TLR: target lesion revascularization; ST: stent thrombosis; OCT: optical coherence tomography; NSTEMI: non-ST-elevated myocardial infarction; PCI: percutaneous coronary intervention.

References

    1. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M. A randomized comparison of a sirolimus- eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 2002;346:1773–1780.
    1. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T. One-year clinical results with the slow- release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947.
    1. Bangalore S., Kumar S., Fusaro M. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873–2891.
    1. Palmerini T., Biondi-Zoccai G., Della Riva D. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393–1402.
    1. Foin N., Lee R.D., Torii R. Impact of stent strut design in metallic stents and biodegradable scaffolds. Int. J. Cardiol. 2014;177:800–808.
    1. Kang S.H., Chae I.H., Park J.J., Lee H.S., Kang D.Y., Hwang S.S., Youn T.J., Kim H.S. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials. J. Am. Coll. Cardiol. Intv. 2016;9(12):1203–1212.
    1. Meredith I.T., Verheye S., Dubois C.L., Dens J., Fajadet J., Carrié D. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J. Am. Coll. Cardiol. 2012;59:1362–1367.
    1. Kereiakes D.J., Meredith I.T., Windecker S., Lee Jobe R., Mehta S.R., Sarembock I.J. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. Circ. Cardiovasc. Interv. 2015 Apr;8(4)
    1. Meredith I.T., Verheye S., Dubois C., Dens J., Farah B., Carrié D. Final five-year clinical outcomes in the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer coated, everolimus-eluting stent. EuroIntervention. 2018;13:2047–2050.
    1. Han Y., Liu H., Yang Y., Zhang J., Xu K., Fu G. A randomized comparison of biodegradable polymer and permanent polymer-coated platinum chromium everolimus-eluting coronary stents in China: the EVOLVE China study. EuroIntervention. 2017;13:1210–1217.
    1. von Birgelen C., Kok M.M., van der Heijden L.C., Danse P.W., Schotborgh C.E., Scholte M. Very thin strut biodegradable polymer everolimus-eluting and sirolimus eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388:2607–2617.
    1. Sarno G., Lagerqvist B., Olivecrona G., Varenhorst C., Danielewicz M., Hambraeus K. Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Catheter. Cardiovasc. Interv. 2017;90:881–887.
    1. Escaned J., Collet C., Ryan N., De Maria G.L., Walsh S., Sabate M. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur. Heart J. 2017;38:3124–3134.
    1. Briguori C., Visconti G., Donahue M., Di Palma V., De Micco F., Signoriello G., Focaccio Performance of the XLIMUS sirolimus-eluting coronary stent in very complex lesions. J. Interv. Cardiol. 2016;29(6):559–568.
    1. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., Byrne R.A., Collet J.P., Falk V., Head S.J., Jüni P., Kastrati A., Koller A., Kristensen S.D., Niebauer J., Richter D.J., Seferovic P.M., Sibbing D., Stefanini G.G., Windecker S., Yadav R., Zembala M.O., ESC Scientific Document Group 2018 ESC/EACTS guidelines on myocardial revascularization. Eur. Heart J. 2019;40(2):87–165.
    1. Prati F., Romagnoli E., Burzotta F., Limbruno U., Gatto L., La Manna A., Versaci F., Marco V., Di Vito L., Imola F., Paoletti G., Trani C., Tamburino C., Tavazzi L., Mintz G.S. Clinical impact of OCT findings during PCI: the CLI-OPCI II study. JACC Cardiovasc. Imaging. 2015;11:1297–1305.
    1. RaÃàber L., Mintz G.S., Koskinas K.C., Johnson T.W., Holm N.R., Onuma Y., Radu M.D., Joner M., Yu B., Jia H., Meneveau N., de la Torre Hernandez J.M., Escaned J., Hill J., Prati F., Colombo A., Di Mario C., Regar E., Capodanno D., Wijns W., Byrne R.A., Guagliumi G. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. EuroIntervention. 2018;14:656–677.
    1. Prati F., Guagliumi G., Mintz G.S., Expert's OCT Review Document Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur. Heart J. 2012;33:2513–2520.
    1. Tearney G.J., Regar E., Akasaka T., International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT) Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J. Am. Coll. Cardiol. 2012;59:1058–1072.
    1. Sotomi Y., Tateishi H., Suwannasom P., Dijkstra J., Eggermont J., Liu S., Tenekecioglu E., Zheng Y., Abdelghani M., Cavalcante R., de Winter R.J., Wykrzykowska J.J., Onuma Y., Serruys P.W., Kimura T. Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography. Int. J. Cardiovasc. Imaging. 2016;32:871–883.
    1. Joner M., Finn A.V., Farb A. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006;48:193–202.
    1. Waksman R., Maluenda G. Polymer drug-eluting stents: is the future biodegradable? Lancet. 2011;378:1900–1902.
    1. Ananthakrishna R., Kristanto W., Liu L., Chan S.P., Loh P.H., Tay E.L. Incidence and predictors of target lesion failure in a multiethnic Asian population receiving the SYNERGY coronary stent: a prospective all-comers registry. Catheter. Cardiovasc. Interv. 2018 Mar;7
    1. Noad R.L., Hanratty C.G., Walsh S.J. Initial experience of bioabsorbable polymer everolimus-eluting synergy stents in high-risk patients undergoing complex percutaneous coronary intervention with early discontinuation of dual-antiplatelet therapy. J. Invasive Cardiol. 2017;29:36–41.
    1. de la Torre Hernandez J.M., Moreno R., Gonzalo N., Rivera R., Linares J.A., Veiga Fernandez G., Gomez Menchero A., Garcia Del Blanco B., Hernandez F., Benito Gonzalez T., Subinas A., Escaned J. The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry. Cardiovasc. Revasc. Med. 2018 Oct 18 (pii: S1553-8389(18)30459-7)
    1. von Birgelen C., Sen H., Lam M.K. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413–423.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe